| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10025563 | HBV | ENSG00000131069.20 | protein_coding | ACSS2 | No | No | 55902 | Q4G0E8 Q6DKJ3 Q96FY7 Q9NR19 |
| TVIS30053433 | HIV | ENSG00000131069.20 | protein_coding | ACSS2 | No | No | 55902 | Q4G0E8 Q6DKJ3 Q96FY7 Q9NR19 |
| TVIS30053434 | HIV | ENSG00000131069.20 | protein_coding | ACSS2 | No | No | 55902 | Q4G0E8 Q6DKJ3 Q96FY7 Q9NR19 |
| TVIS20005833 | HPV | ENSG00000131069.20 | protein_coding | ACSS2 | No | No | 55902 | Q4G0E8 Q6DKJ3 Q96FY7 Q9NR19 |
| TVIS20043403 | HPV | ENSG00000131069.20 | protein_coding | ACSS2 | No | No | 55902 | Q4G0E8 Q6DKJ3 Q96FY7 Q9NR19 |
| TVIS44021380 | HTLV-1 | ENSG00000131069.20 | protein_coding | ACSS2 | No | No | 55902 | Q4G0E8 Q6DKJ3 Q96FY7 Q9NR19 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | ACSS2 |
|---|---|
| DrugBank ID | DB00131 |
| Drug Name | Adenosine phosphate |
| Target ID | BE0000350 |
| UniProt ID | Q9NR19 |
| Regulation Type | product of |
| PubMed IDs | 17350930; 17303131; 16981708; 17497934 |
| Citations | Ingram-Smith C, Smith KS: AMP-forming acetyl-CoA synthetases in Archaea show unexpected diversity in substrate utilization. Archaea. 2007 May;2(2):95-107.@@Linne U, Schafer A, Stubbs MT, Marahiel MA: Aminoacyl-coenzyme A synthesis catalyzed by adenylation domains. FEBS Lett. 2007 Mar 6;581(5):905-10. Epub 2007 Feb 7.@@Ingram-Smith C, Woods BI, Smith KS: Characterization of the acyl substrate binding pocket of acetyl-CoA synthetase. Biochemistry. 2006 Sep 26;45(38):11482-90.@@Reger AS, Carney JM, Gulick AM: Biochemical and crystallographic analysis of substrate binding and conformational changes in acetyl-CoA synthetase. Biochemistry. 2007 Jun 5;46(22):6536-46. Epub 2007 May 12. |
| Groups | Approved; Investigational; Nutraceutical; Withdrawn |
| Direct Classification | Purine ribonucleoside monophosphates |
| SMILES | NC1=C2N=CN([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]3O)C2=NC=N1 |
| Pathways | Leigh Syndrome; Histidinemia; Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency); Fatty Acid Metabolism; Gentamicin Action Pathway; Pyruvate Dehydrogenase Complex Deficiency; Purine Nucleoside Phosphorylase Deficiency; Hyperprolinemia Type II; Glutamate Metabolism; Clarithromycin Action Pathway; Argininosuccinic Aciduria; Pyruvate Decarboxylase E1 Component Deficiency (PDHE1 Deficiency); Hyperinsulinism-Hyperammonemia Syndrome; Butyrate Metabolism; Pyruvate Metabolism; Pentose Phosphate Pathway; Propanoate Metabolism; Glycine and Serine Metabolism; Selenoamino Acid Metabolism; Thiamine Metabolism; Oxytetracycline Action Pathway; Tetracycline Action Pathway; Carbamoyl Phosphate Synthetase Deficiency; Hyperprolinemia Type I; Histidine Metabolism; Cystathionine beta-Synthase Deficiency; Arginine and Proline Metabolism; Roxithromycin Action Pathway; Purine Metabolism; Ammonia Recycling |
| PharmGKB | PA164744376 |
| ChEMBL | CHEMBL752 |
